MTM improves adherence 30% over standard of care for IBD

Preliminary results of a new study indicate that medication therapy management (MTM) increased adherence more than 30% compared with standard of care for patients with inflammatory bowel disease (IBD). In the Project A.L.I.V.E.

Preliminary results of a new study indicate that medication therapy management (MTM) increased adherence more than 30% compared with standard of care for patients with inflammatory bowel disease (IBD). In the Project A.L.I.V.E. (Adherence and Long-term IBD Value-added Effectiveness) study, about 55% of patients in the intervention group that received MTM had improved adherence compared with 25% in both control groups. In addition, while 3.4% of the intervention group saw decreased adherence, the rates of decreased adherence in the two control groups were 20.8% and 25%, respectively. "Project A.L.I.V.E. is well on its way to measuring program value for IBD patients and caregivers with preliminary results showing improved adherence in the treatment arm," said Curant Health Director of Clinical Pharmacy Vickie Andros, PharmD. "We anticipate that our enhanced medication therapy management and patient support services will continue to demonstrate project value through outcomes improvement and impact on cost through a reduction in hospitalizations and ED visits for this patient population." Andros and Sharon Dudley-Brown, MD, principal investigator and Assistant Professor of Medicine at Johns Hopkins University, reported their findings in a poster presentation at the 2016 American College of Gastroenterology Annual Scientific Meeting.